Novartis AG (NOVN.SW, SIX) closes CHF117.48 on 24 Mar 2026: 3.25M shares most active

NOVN.SW stock closed at CHF117.48 on 24 Mar 2026 as the market ended, with 3,245,741 shares traded. The session made Novartis AG one of Switzerland’s most active names on the SIX exchange. Price moved up 1.36 CHF, or 1.17%, from the prior close. Traders cited heavy turnover and sector dynamics in healthcare as drivers of the session.

Market close summary and volume drivers

Novartis AG (NOVN.SW) finished the session at CHF117.48 on the SIX in Switzerland, up 1.36 CHF from CHF116.12. The intraday range was CHF115.66 to CHF117.68, and volume reached 3,245,741 shares versus a 30-day average of 3,440,649. High activity came as investors rotated within healthcare toward defensive large caps amid mixed sector flows. For company profile and background, see MarketWatch source.

Why NOVN.SW stock was most active today

Volume on NOVN.SW rose as investors adjusted exposure to large-cap healthcare. Novartis traded near its 50‑day average price of CHF120.97 and above the 200‑day average of CHF106.32, attracting both momentum and value traders. Sector rotation into defensive healthcare names and ongoing interest in Novartis’ pipeline and Sandoz positioning supported activity. Bloomberg noted broader fund movements on the SIX as part of the session context source.

Fundamentals and valuation snapshot for NOVN.SW stock

Novartis reports EPS of CHF5.67 and a trailing P/E of 20.72. Market cap stands at CHF224.17B. The company pays CHF4.68 per share in dividends, a yield near 3.15%, with a payout ratio of 53.54%. Key ratios show price to sales of 5.04 and price to book near 6.17. Revenue per share is CHF29.41 and free cash flow per share is CHF8.76, underlining healthy cash generation despite premium multiples.

Technical picture and short-term signals

Technicals on NOVN.SW stock are mixed. RSI sits at 38.77, showing modest downside momentum. MACD histogram is negative at -1.10, and ADX reads 29.45, implying a defined trend. Bollinger bands run CHF113.87–CHF132.13, and ATR is CHF2.53, highlighting moderate volatility. Short-term traders should watch a break of CHF115.66 for support and CHF120.97 as the immediate resistance tied to the 50‑day average.

Meyka Grade and model forecast for NOVN.SW stock

Meyka AI rates NOVN.SW with a score out of 100: 78.12, Grade B+, Suggestion BUY. This grade factors S&P 500 and sector comparison, financial growth, key metrics, and analyst signals. Meyka AI’s forecast model projects a quarterly target of CHF137.85, a yearly level of CHF117.11, and a five‑year value of CHF162.70. The quarterly forecast implies an upside of 17.35% from today’s CHF117.48. Forecasts are model-based projections and not guarantees.

Risks, catalysts and sector context

Primary risks for NOVN.SW stock include pricing pressure in generics via Sandoz, patent timing, and regulatory outcomes. Catalysts include upcoming earnings on 28 Apr 2026, pipeline readouts, and potential M&A. Within Healthcare on the SIX, Novartis trades cheaper than some peers on growth metrics but at a premium on book value. Investors should weigh dividend yield, R&D intensity near 19.37% of revenue, and net debt metrics when sizing positions.

Final Thoughts

Novartis AG (NOVN.SW) finished the market closed session at CHF117.48 on 24 Mar 2026 with strong turnover at 3,245,741 shares. The stock remains a core large‑cap in Swiss healthcare, supported by CHF8.76 free cash flow per share and a 3.15% dividend yield. Valuation is mixed: a trailing P/E of 20.72 and price to book of 6.17 reflect premium expectations. Meyka AI’s models show short windows for both upside and consolidation. The quarterly projection of CHF137.85 implies a 17.35% upside, while the one‑year model at CHF117.11 is essentially flat, implying -0.31% versus today’s price. Traders should treat the forecasts as model outputs, not guarantees. For a quick company profile and filings, visit our Meyka page at Meyka NOVN.SW. Overall, NOVN.SW stock offers steady cash flow and dividend income, with upside tied to clinical and commercial catalysts and downside from Sandoz margin pressure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.